888casino88freespins| The overall A-share market fluctuated at a low level, and Azure Biotech experienced five consecutive daily limits

Original title: just now, rising and falling tide! There is a stock 5 connected board!

This morning, the A-share market as a whole fluctuated at a low level, led by the defense and military industry plate. After a big net purchase yesterday, Beixiang sold a net fund of about 3.3 billion yuan this morning.

It is worth noting that a number of A-share stocks continued to rise by the limit this morning, of which stocks have risen by the limit for five times in a row, and related companies warned of risks last night.

The Hong Kong stock market adjusted slightly this morning.

The A-share market as a whole fluctuated at a low level and the military industrial sector led the rise.

The overall low of the A-share market fluctuated this morning. By the close of trading in the morning, the Shanghai Composite Index was down 0%.888casino88freespins.13%.

Industry plate and track, the defense industry plate led the rise, Hangxin Technology, Andaville intraday hit the "20cm" trading limit, and many stocks rose by the limit or more than 10%.

Basic chemical industry, non-ferrous metals, agriculture, forestry, animal husbandry and fishery and other sectors ranked in the forefront of the market.

Communications, utilities, machinery and other sectors led the decline in the morning.

The overall performance of the computer plate was weak in the morning, but the plate leader 360 hit the daily limit at one time. Guohua Wangan (rights protection) also touched the daily limit.

After a big net purchase yesterday, Beixiang sold a net fund of about 3.3 billion yuan this morning.

A number of stocks continue to rise by the limit. Existing stocks have risen by the limit for five consecutive times.

It is worth noting that a number of stocks continued to rise by the daily limit this morning, and the relevant companies warned of the risks last night.

Fujilai touched the "20cm" limit in intraday trading this morning, which is the third consecutive day in which the stock touched the "20cm" limit.

Fujilai issued a notice of abnormal volatility in stock trading last night, saying that the company is concerned about the discussion of the company's business on some self-media, stock bars and other platforms involving synthetic biology and related hot concepts. The biological enzyme catalytic method is the development trend of the preparation of R-lipoic acid. The R-lipoic acid produced by the company's biological enzyme catalytic method has achieved mass production, which is mainly used for external sales and preparation of R-lipoic acid sodium salt, which is still in the market promotion stage. Whether it can completely replace the original process depends on market demand, customer acceptance and other factors. In 2023, this kind of business income accounts for no more than 3% of the company's operating income, which is relatively small, and there is no clear plan to expand production for the time being. Investors are respectfully invited to pay attention to investment risks, rational decisions and prudent investment.

In addition, Fujilai last night also issued an announcement on obtaining a renewed "drug production license". According to the notice, the main content of this change is the newly commissioned production (for registration and declaration only): the trustee is Zhejiang Saimo Pharmaceutical Co., Ltd., the entrusted variety is lipoic acid tablets, and the production site is No. 788 Yonghu Street, Tangxi Town, Wucheng District, Jinhua City, Zhejiang Province. the entrustment is valid for September 20, 2025. This change will help the company to optimize the production structure and better meet the market demand. It has no significant impact on the company's performance in the short term, so investors are invited to pay attention to the investment risk.

Azure Bio once again hit the daily limit, which is the fifth consecutive trading day to hit the limit.

Azure Bio issued an announcement of abnormal volatility in stock trading last night, saying that recently, the company has been concerned about the Internet and some media reports on "synthetic biology." According to the announcement, the company's main business is the research and development, production and sales of enzyme preparations, microecological preparations and animal health products. According to the company's 2023 annual report, the revenue of enzyme preparation is 441.4485 million yuan, accounting for 37.49% of the main business income.888casino88freespinsThe income from microecological products is 237.1405 million yuan, accounting for 20.14% of the main business income; the income from animal health products is 297.23 million yuan, accounting for 25.24% of the main business income; and the income from other products is 201.6028 million yuan, accounting for 17.12% of the main business income. The synthetic biotechnology innovation laboratory disclosed in the company's previous periodic report is mainly used for the research and development of functional proteins and sweeteners, but the reserve R & D projects are less and the investment is relatively small, so it is still in the pre-R & D stage and does not have the conditions for industrialization. The company has found no other media reports or market rumors that need to be clarified or responded to; the company has not found any other major events that may have a greater impact on the company's share price.

Societe Generale shares hit the daily limit for the third consecutive trading day.

Societe Generale issued a notice on abnormal fluctuations in stock trading last night, saying that the company's stock closed with a cumulative deviation of 20% for three consecutive trading days on April 29, April 30 and May 6, 2024. According to the relevant provisions of the Stock Exchange rules of the Shanghai Stock Exchange, it belongs to the case of abnormal fluctuations in stock trading. According to the announcement, it has been verified by the company and confirmed by letter to the company's controlling shareholders and actual controllers that there is no material information that should be disclosed but not disclosed. The board of directors of the company confirmed that the daily business activities of the company were normal and that there were no major matters affecting the abnormal fluctuation of the company's stock trading price.

Hong Kong stock market adjusts slightly in the morning

The Hong Kong stock market adjusted slightly this morning.

Among the constituent stocks of the Hang Seng Index, Orient overseas International and Lenovo Group led the rise.

Among the stocks whose share prices fluctuated sharply in the Hong Kong stock market, Nanjing Panda shares rose more than 10% in intraday trading. The company announced last night that the financing guarantee for subsidiary companies approved by Nanjing Panda Electronics Co., Ltd. at its 2022 annual general meeting will expire on the date of the 2023 annual shareholders' meeting.

In view of the fact that these subsidiaries have requested the company to continue to provide guarantees for their financing, the company takes into account the production and operation of these subsidiaries and their actual capital requirements, it is proposed to agree to provide guarantees for the total amount of financing of these subsidiaries not exceeding RMB 95 million during the period from the day following the end of the 2023 annual general meeting to the date of the 2024 annual general meeting. This time, there is no counter-guarantee for the financing of subsidiaries.

Editor: Zhu Yumeng

Proofreading: Wang Chaoquan